Announcing Nilo Therapeutics: $101M for Immune Disease Drugs
Nilo Therapeutics has closed a $101 million Series A and named Kim Seth as chief executive officer and board...
EU Patent Office Approves ARS Pharma’s Neffy Nasal Spray
ARS Pharmaceuticals secured a significant intellectual property win in Europe, with the European Patent Office’s Opposition Division upholding all...
Lexicon’s New Focus: Addressing Gaps in Chronic Pain Policy
Lexicon Pharmaceuticals convened a policy roundtable in Washington, DC, centered on expanding federal support for non-opioid pain treatments. The...
Abeona & Children’s Hospital CO Open New Gene Therapy Center
Abeona Therapeutics has activated Children’s Hospital Colorado as a qualified treatment center for Zevaskyn (prademagene zamikeracel), the first FDA-approved...
Nilo Therapeutics Launches with $101M for Immune Disease
Nilo Therapeutics has launched with a $101 million Series A to develop drugs that modulate neural circuits to restore...
Revolutionary Tech for Disease Diagnosis Arrives in Newcastle
Newcastle University has partnered with Curium to establish a PET radiopharmaceutical manufacturing site in Newcastle, expected to be operational...
Zenas & InnoCare Announce Promising Autoimmune Drug Deal
Zenas Biopharma has secured a global license from InnoCare Pharma to develop and commercialize orelabrutinib for multiple sclerosis and...
New Partnership Accelerates Drug Development for Innovators
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions have launched an integrated CMC partnership to deliver end-to-end...
Reviva to Participate in Key Opinion Leader (KOL) Webinar
Reviva Pharmaceuticals is convening a key opinion leader webinar on October 10 to discuss Phase 3 data for brilaroxazine,...
New Hope for GLP-1 Nausea: NG101 Proof-of-Concept Data
Neurogastrx will present proof-of-concept data for NG101, an oral, peripherally restricted dopamine D2 receptor antagonist (metopimazine mesylate), in semaglutide-induced...